International Clinical Trial: Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07195695) titled 'Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment' on Sept. 25.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Boehringer Ingelheim

Condition: Non-small Cell Lung Cancer

Intervention: Drug: Zongertinib Drug: Pembrolizumab Drug: Atezolizumab Drug: Durvalumab

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: December 5, 2025

Target S...